Effect of Intravenous Saccharated Ferric Oxide on Serum FGF23 and Mineral Metabolism in Hemodialysis Patients
Not Applicable
- Conditions
- Hemodialysis patients with iron-deficiency anemia
- Registration Number
- JPRN-UMIN000004814
- Lead Sponsor
- kobe university school of medicine, division of nephrology and kidney center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
exclude a patient with menstruation, active gastrointestinal hemorrhage, tumor-bearing, hematological disorder, hepatitis and liver cirrhosis, secondary hyperparathyroidism (intact parathyroid hormon more than 500 pg/ml), parathyroidectomy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of FGF23, and Mineral metabolism
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does intravenous saccharated ferric oxide modulate serum FGF23 levels in hemodialysis patients with iron-deficiency anemia?
What is the comparative efficacy of saccharated ferric oxide versus iron sucrose on mineral metabolism in hemodialysis patients?
Which biomarkers correlate with improved iron status after saccharated ferric oxide administration in CKD stage 5 anemia?
What adverse events are associated with saccharated ferric oxide in hemodialysis patients compared to ferumoxytol?
How do saccharated ferric oxide mechanisms differ from other IV iron formulations in managing FGF23-related complications in dialysis?